AgingResearch.NewsJoin free

Biosplice

CompanyUnited States

Biosplice develops one asset, approved (Lorecivivint in knee osteoarthritis). Mostly small molecule acting on DYRK1A, inflammation and CLK2; based in the United States.

1
Asset
Furthest stage
Approved
0
Trials
0
Signals

Pipeline

1

  • Lorecivivint

    Inhibits CLK2 and DYRK1A, modulating alternative splicing and downstream Wnt signaling to reduce inflammation and protect cartilage.

    Approved, Small molecule, DYRK1A, Inflammation, knee osteoarthritis, meniscal injuries (Phase 3)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • People9
  • Similar companies6

Intelligence